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ABSTRACT
Bacterial L-Asparaginase has been utilized along with chemotherapy in the treatment of
acute lymphoblastic leukemia. Current forms of treatment are fraught with undesirable outcomes
in a significant number of cases. This has led to a continued investigation of other bacterial
sources of L-asparaginase.
Rhodococcus rhodochrous strain DAP 96253 when induced on specialized media was
found to present L-asparaginase and L-glutaminase activity. A purification scheme was
developed evaluating the effect of the method of cell lysis, the use of a reducing agent and

dialysis on the final product. A protein preparation was purified from the crude extract
employing dialysis, anion exchange and size exclusion chromatography using a Hitrap®Q HP
and a HiprepTM 16/60 SephacrylTM S500HR column respectively. The purified protein exhibited
1492 and 2173 IU/mg of L-asparaginase and L-glutaminase respectively.
Further kinetic studies of the purified preparation demonstrated an optimum reaction pH
at 7.6, maximal enzyme activity at 37°C and stability exceeding 60 minutes. The Km for Lasparagine and L-glutamine were determined to be 13.6µM and 850µM respectively. The protein
was determined to be stable in human serum at 37ºC with a T1/2 of approximately 53 hours.
Endotoxins were 771 times less than an Escherichia coli sample, with the endotoxins detected
being introduced during the purification process, the three subunits of the protein were estimated
to be ~72, 28 and 23kDa versus a homotetrameric protein in E. coli, and the protein was
determined to be effective in reducing the cell number and viability of Jurkat E6-1 clone and
Molt-4 cells exhibiting an IC50 of 0.123 and 1.982 IU/mg respectively. This is the first attempt to
characterize an L-asparaginase from R. rhodochrous.
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1

INTRODUCTION

1.1 Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is the most prevalent form of childhood cancer in
the United States of America, accounting for 80% of leukemias specifically and 25 to 26% of all
cancers observed in children and about 8% in adolescents with peak incidence in individuals
between the ages of 2 and 5[9,53,107]. Incidence rates are much lower in adults with ALL
accounting for less than 1% of adult cancers[53]. Analysis of ALL occurrence rates in the USA
from 2001 to 2014 showed an average occurrence rate of 34.1 per 1 million individuals, with the
highest occurrence among Hispanics at 42.9 per million individuals. Caucasians had a slightly
lower incidence rate at 34.2 per million individuals and African Americans had the lowest
incidence rates at 18.7 per million individuals. Incidence rates are also slightly higher in male
children when compared to females (̴1.28 times higher in males)[95,7].

Figure 1: Annual age adjusted rates of ALL among children by State National Program of Cancer Registries, and
Surveillance, Epidemiology and End Results Program, United States, 2001-2014 [Siegel et al., 2017].
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Figure 2: a: Trends in age-adjusted rates of acute lymphoblastic leukemia in children by sex and b; race/ethnicity
[Siegel et al., 2017, Barrington-Trimis et al., 2017]

3

On a global scale, based on the data collected from 2003 to 2007, Incidence rates of ALL
stand at 10.8 to 21.2 per million individuals with higher incidence rates in the Americas and
Oceania and lower rates in Asia and Eastern Europe[53]. There are an estimated 6000 new cases
of ALL accounting for 0.3% of new cancer cases in the USA and 1500 deaths, accounting for
0.2% of all cancer related deaths all in 2019 alone[81].
The pathogenesis of ALL is characterized by an unusual proliferation and differentiation
of a clonal population of lymphoid progenitor cells which never achieve maturation and stymy
the production of healthy lymphocytes. Predisposing conditions that can lead to this abnormal
proliferation in a small number of cases include Fanconi anemia, Bloom syndrome, Down
syndrome, Human immunodeficiency virus, Epstein Barr virus, ataxia telangiectasia and
Nijmegen breakdown syndrome[94,41,10,14,44,40]. Ionizing rays, pesticides and to a lesser
degree, electromagnetic fields and cigarette smoke are also included as other predisposing
factors that influence the onset of ALL[8,46].
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Figure 3: Demonstrates the normal path of differentiation of HSCs to become B lymphocytes, T lymphocytes or NK
cells and the uncontrolled proliferation of lymphoid progenitor cells that occurs with ALL.

The disease condition is characterized by symptoms such as bone pain, osteolytic lesions,
osteonecrosis, extremity and joint pain, fever, nausea, night sweats, weight loss, easy bruising,
bleeding, dyspnea, dizziness and increased susceptibility to diseases[77,52,56,33].
Hematopoietic stem cells (HSCs) are progenitors for B and T lymphocytes as well as natural
killer cells, all of which constitute an important part of the human immune system[108].
Throughout a human’s life, HSCs provide a steady supply of B and T lymphocytes, with a
massive production of lymphocytes during fetal and neonatal periods but lymphocyte production
especially T lymphocytes slows down after adolescence[50]. The site of differentiation
determines the fate of the progenitor HSCs with B lymphocytes formed from lymphoid
progenitor cell differentiation in the bone marrow (liver in fetus) and T lymphocytes from
lymphoid progenitor cell differentiation in the thymus. This means then that based on
immunophenotypes, there are two subtypes of ALL; the B cell and T cell ALL[93,64,17].
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A whole host of genetic factors has been implicated in the onset of ALL[97].Wiemels et
al., is believed to be the first to draw a correlation between ALL and genetic anomalies. The study
identified TEL-AML1 gene fusion which when expressed results in the inhibition of B cell
differentiation leading to massive accumulation of B cell progenitors and a correlated reduction in
mature B lymphocytes[109]. Another example of a genetic anomaly associated with ALL is the
Philadelphia chromosome; characterized by genetic mutations that activate several signaling
pathways such as those concerned with cytokine receptors, tyrosine kinases and epigenetic
modifiers. Philadelphia chromosome-like ALL constitutes 10% and 13% of standard and high-risk
childhood B lineage ALL respectively. The frequency of incidence of the Philadelphia
chromosome-like ALL also increases with age making for very poor survival in adult
ALL[112,92]. In 40% of B lineage ALL cases, deletions, amplifications, mutations and structural
rearrangements in key transcription factors that influence early lymphoid differentiation have been
observed[112]. In particular, mutations of the IKZF1 gene encoding the IKAROS transcription
factors which is vital for the induction of B lymphocyte differentiation has been associated with
poor prognosis of ALL[39,79,112] and mutations in tumor suppressor genes have also been
implicated in childhood ALL[54]. Ultimately, the fate of the affected cells is the same; massive
proliferation of immature lymphoid progenitor cells which undercuts the number of healthy
lymphocytes. The current form of treatment for ALL includes the use of L-asparaginase along with
chemotherapy.
1.2 Asparaginase (ASNase)

L Asparaginase (ASNase) is an enzyme that catalyzes the hydrolysis of L-asparagine
(ASN) to L-aspartic acid and ammonia[74,55]. Bacterial ASNase enzymes obtained from
Escherichia coli have been classified into two subtypes based on their intrinsic location in a
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bacterial cell as well as their substrate affinity. Subtype I isolated from the cell cytosol has a
lower affinity for ASN while subtype II isolated from the periplasm has a much higher substrate
affinity for ASN[74]. The enzymatic activity of ASNase was first discovered by Lang who
observed ASNase activity in several beef tissues in 1904, this was confirmed in 1910 by Furth
and Fredmanm. Clementi discovered in 1922 that ASNase was active in all herbivore tissues
(particularly in guinea pig serum), omnivore livers and absent in tissues of carnivores,
amphibians and reptiles[74,60]. The anticancer capabilities of guinea pig serum against mouse
and rat lymphomas were first reported by Kidd et al., in 1953 and this particular capability was
later attributed to the ASNase present in guinea pig serum[13]. Shortly after, an ASNase isolated
from E. coli was shown to possess significant anti-tumor capabilities and this spurred a flurry of
research into E. coli ASNases and eventually led to its approval for clinical trials for anticancer
treatment, making it the first ASNase used as an antileukemic treatment.[91,12,47,20,82].
ASNase is employed as an antileukemic because of its ability to hydrolyze ASN to L
aspartate and ammonia. ASN is a vital amino acid required by the leukemic lymphoid progenitor
cells for their survival. Leukemic lymphoid progenitor cells are usually incapable of synthesizing
this amino acid and utilize blood serum ASN for their metabolism. Normal cells expressing the
asparagine synthetase gene are capable of synthesizing ASN and are not negatively impacted by
ASN deficit brought about by the use of ASNase[86,63,32]. The absence of ASN results in
inability of the leukemic cells to synthesize proteins and this arrests their development and leads
to their subsequent apoptosis[100]
There are three ASNases currently approved to be used as part of chemotherapeutic
cocktail. Native E. coli ASNase trademarked under the name Elspar, a pegylated form of native
E. coli ASNAse also known Oncospar and ASNase derived from Erwinia chrysanthemi also
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known as Erwinaze[35]. Erwinaze is approved for use only in Europe and is used in the USA
only under compassionate recourse

Figure 4: The hydrolytic effect of ASNase on ASN and its subsequent antileukemic effect [adapted from Elshafei et
al.,2012]

The use of ASNase has significantly improved the outcome of treatment of ALL. Since
the introduction of ASNase as a form of treatment, the survival rate of individuals with this
disease condition has progressively increased from almost universally fatal to about 90% in
children[28] and 78% in young adults[58]. These numbers, however, are only applicable to
individuals who do not develop a treatment preventing condition. A study showed that patients
treated using chemotherapy incorporating ASNAse had increased survivability when compared
to patients treated using chemotherapy not incorporating ASNase, indicating that ASNase
chemotherapy is significant for the successful treatment of ALL[28].
The use of ASNase as a form of treatment for ALL is not without its risks, studies have
shown toxicities in up to 30% of treated patients with the most prevalent form of toxicity being
hypersensitivity[90,106], other toxicities include pancreatitis, liver dysfunction, diabetes,
coagulation abnormalities and thrombosis which is particularly common in adult patients with
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ALL[58,26]. Both organisms used as sources for ASNase are Gram-negative bacteria which
therefore possess lipopolysaccharide Endotoxins as integral membrane structures and
lipopolysaccharides have been implicated in human hypersensitivity to Gram-negative bacterial
cells and their products.[38,37] A study showed 41% of observed patients treated with E. coli
ASNase showed an allergic reaction, 12.5% of these patients with allergic reactions who were
then switched to Erwinia derived ASNase showed an allergic reaction while 33.3% showed an
allergy to pegylated E. coli ASNase indicating increased toxicity to E. coli when compared to
Erwinia ASNase[66,28]. It is noteworthy that E. coli ASNase has been shown to have a higher
efficacy than Erwinia ASNase. Comparative toxicity and efficacy of the two ASNases showed
that when patients are treated with the same dosage (10,000 IU,m2), ASNase obtained from E.
coli had higher coagulation abnormalities but similar toxicities to those treated with Erwinia
ASNase, while a higher number of patients on Erwinia ASNase failed to achieve complete
remission[26] indicating that ASNase derived from E. coli are more effective but with more side
effects when compared to ASNase derived from E. chrysanthemi[27]. Elspar derived from E.
coli has a half-life of 8 to 30 hours, Oncospar, the polyethylene conjugated ASNase formulation
also prepared using E. coli derived ASNase has a half-life of about 6 days while Erwinaze
derived from E. chrysanthemi has a half-life of 16 hours[111]. The reduced half-life of Erwinaze
is probably tied to its reduced efficacy when compared to the E. coli formulations. Other
problems associated with ASNase therapy are susceptibility to proteases and the development of
serum antibodies that inactivate the protein, and this has been shown to occur both in patients
with and without hypersensitivity to the protein[104,15,84].
Another major problem associated with the use of currently approved ASNases are their
inherent L-Glutaminase (GLNase) activity. This activity has been linked to several side effects
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associated with ASNase therapy, side effects such as hepatotoxicity, hyperglycemia, and
dyslipidemia[80]. Some studies suggest that this inherent GLNase activity is vital to induce
apoptosis in lymphoblasts especially those expressing the Asparagine synthetase (ASNS) gene
and are therefore capable of synthesizing ASN from serum Glutamine (GLN)[18,85].
ASNase has been isolated from a wide variety of lifeforms such as animal tissue, fungi
and plants[76,13,96], however, only bacterial ASNases have been approved for use in the
treatment of leukemia. The source and growth conditions fundamentally influence the properties
of the isolated ASNases such as substrate affinity, optimum temperature, optimum pH, and
structural diversity. The problems associated with the currently approved ASNases have led to
increased investigations of other bacterial ASNases as potential alternatives to the currently
approved ones in the hope of circumventing the problems associated with their use for cancer
therapy.
1.3 Rhodococcus rhodochrous

Members of the genus Rhodococcus are aerobic, non-spore forming, non-motile,
mycolate containing, Gram-positive bacteria that are largely ubiquitous and classified along with
Corynebacterium, Mycobacterium and Nocardia under the phylum Actinobacteria due largely to
morphological similarities[36,103,6]. The genus ‘Rhodococcus’ was settled upon after
Mycobacterium, Nocardia and Corynebacterium were offered as possible genera under which to
classify microbes that possessed the “Rhodochrous effect”[43]. The rhodochrous effect was used
to describe bacteria from which mycolic acids have been isolated[75]. The mycolic acids isolated
from bacteria within the Rhodochrous complex are composed of hydrocarbon chain lengths
centered around C40, which separates them from the genera Corynebacterium and Norcadia that
have mycolic acids with chain length around C20 to C30 and C50 respectively[3].

10
Members of this genus are characterized by high guanine/ cytosine DNA content[6], cell
wall components that include A-acetylglucosamine, N-acetyl glucomuramic acid, D-and Lalanine, D-glutamic acid, mesodiaminopimelic acid, arabinose, galactose, cardiolipin,
phosphatidylinositol mannosides, and mycolic acids with 34-52 carbon atoms[36] and the
presence of carotenoids which are believed to be responsible for the characteristic red, orange,
pink and yellow pigmentation of most Rhodococci[98].
Another notable characteristic of the members of the genus Rhodococcus is their
unusually large genome, A study by McLeod et al., in 2006 identified a 9.7 mbp genome with a
67% guanine/ cytosine content arranged in a linear chromosome and three linear plasmids
(pRHL1, pRHL2, and pRH3) in Rhodococcus sp RHA1, the largest genome observed in a
prokaryote to date[70]. This unusually large genome size is credited for the massive enzyme
suite typically observed in members of the genus Rhodococcus, of particular interest are the large
number of genes that were identified that were involved with secondary metabolism, including
genes for polyketide and peptide synthase indicating prolific antibiotic production[31]. Members
of this genus have also been demonstrated to produce biosurfactants and bioflocculants[36,62].
Biosurfactants specifically have been demonstrated to be indispensable for waste cleanup as they
increase the surface area of hydrophobic insoluble substances, essentially functioning as bioemulsifiers[83] and facilitating the degradation of these substances by water based enzymes.
Moreover, the hydrophobic surface area of Rhodococci has been implicated in their adhesion to
hydrocarbons essentially enhancing their biodegradative capabilities against hydrocarbons
specifically[73]. Flocculants aid in the collection of suspended matter such as solids and colloid
particles and is vital in water purification process, wastewater treatment, activated sludge
treatment and food fermentation[1]. The biosurfactant and bioflocculant production by members
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of the genus Rhodococcus suggests that these organisms can be utilized broadly for industrial
processes. In addition to waste management, some members of the genus Rhodococcus have also
been demonstrated to bioaccumulate heavy metals such as lead, mercury and copper[5,25].
R. rhodochrous strain DAP 96253 when induced by growth on media incorporating Urea
and Cobalt (II) chloride are capable of increased production of certain enzymes of interest. Some
of the enzymes upregulated by media incorporating urea and cobalt (II) chloride include Nitrile
hydratase (NHase), ASNase, GLNase, and Amidase. Past and ongoing studies at the Pierce lab
have shown that a catalyst derived from induced cells of R. rhodochrous DAP 96253 can delay
the ripening process of climacteric fruits. An elaborate scheme explaining the pathways utilized
by the catalyst to impede the Yang cycle which is responsible for the ripening of climacteric
fruits was put forward and it included the activities of enzymes such as NHase, amidase,
cyanidase, 1 aminocyclopropane 1 carboxylic acid deaminase (ACC deaminase), β cyanoalanine
synthase (β CAS), isocitrate lyase, monooxygenase and epoxide hydrolase (1-HMO).[87,88]
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Figure 5: The Yang cirlce describing the conversion of methionine to ethylene and HCN and CO2 which
have been implicated in the ripening process and the effect of selected enzymes (highlighted in red) and their impact
on delaying the ripening of climacteric fruits [adapted from Pierce et al., 2014]

Along with the ability to delay the ripening of fruits, R. rhodochrous DAP 96253 has also
been found to fungicidal and fungistatic. Closed airspace, contact independent setups using
induced cells of R. rhodochrous DAP 96253 against Pseudogymnoascus destructans, the fungus
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responsible for the fatal white nose syndrome in North American bats showed that the R.
rhodochrous totally inhibited the conidial growth of P destructans at 15ºC and was strongly
fungistatic at 4ºC[22].
Induced cells of R. rhodochrous DAP 96253 have also been demonstrated to be to
fungicidal against the fungus Ophidiomyces ophiodiicola which has been implicated in fatality of
snakes in 15 American states[21]. The delayed ripening and fungicidal and fungistatic properties
observed in R. rhodochrous strain DAP 96253 and other interesting metabolic capabilities
associated with other species of Rhodococcus is typically attributed to their unusually large
genome[103]. The metabolic capabilities of R. rhodochrous DAP 96253 coupled with it being a
Gram-positive organism suggests that ASNase and GLNase purified from this organism could
circumvent some of the issues plaguing currently approved ASNases.

Figure 6: a; Closed headspace setup showing complete inhibition of O. ophiodiicola by packed cells of Induced R.
rhodochrous DAP 96253 and b; growth of O. ophiodiicola in the absence of R. rhodochrous [Cornelison et al.,
2016]
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1.4 Objectives

The main objective of this research project was to investigate classical methods of protein
purification to determine optimum protein purification methods resulting in a reproducible
protein preparation exhibiting stable ASNase and GLNase activity obtained from induced cells
of R. rhodochrous strain DAP 96253 that can serve as alternative antileukemic treatment for
ALL.
Upon completion of this objective, other studies were performed to determine
a. The levels of enzyme production by induced cells of R. rhodochrous DAP 96253
employing various induction media
b. The optimum buffer pH for protein purification,
c. The stability of the purified protein at a defined pH and temperature range.
d. The stability of the purified protein in sterile human serum
e. long term storage stability at subzero temperatures,
f. endotoxin analysis, and
g. determination of the efficacy of the purified protein against selected leukemia expressing
cell lines.
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MATERIALS AND METHODS

2.1 Media and organisms
1. Yeast extract, malt extract agar (YEMEA/ Co/ U); 4g dextrose anhydrous (Fisher
chemical), 4g Yeast extract (BD BactoTM), 10g Malt extract (BD BactoTM), 0.1g Cobalt II
chloride (Sigma Aldrich), 20g Technical agar (BD DifcoTM), dissolved in 850 mL of
deionized water. More deionized water is added to reach a final volume of 0.95L and
autoclaved. 7.5g of Urea (Fischer chemical) was filter sterilized and added to the molten
agar after it had cooled to below 50ºC to reach a final volume of 1L. Plates are made by
aseptically pipetting 25 mL of molten agar into sterile petri dishes.
Yeast extract, malt extract broth (YEMEA/ Co/ U); 4g dextrose anhydrous (Fisher
chemical), 4g Yeast extract (BD BactoTM), 10g Malt extract (BD BactoTM), 0.1g Cobalt II
chloride (Sigma Aldrich), all dissolved in 850 mL of deionized water and autoclaved.
7.5g of Urea (Fischer chemical) was dissolved into 150 mL of deionized water and filter
sterilized into the broth when it had cooled to room temperature (RT).
2. Modified R3A media (mR3A); 3g Proyield cotton (FrieslandCampina), 1.5g soluble
starch (BD DifcoTM), 1.5g yeast extract (BD BactoTM), 0.15g Magnesium sulfate
anhydrous (J.T. Baker), 0.90g potassium phosphate dibasic (EMD Millipore), and 0.1g
Cobalt II chloride (Sigma-Aldrich), dissolved in 1L of deionized water and autoclaved.
10g dextrose anhydrous (Fisher chemical), 16g Urea (fisher chemical) and 0.76g Sodium
pyruvate (Sigma-Aldrich) are dissolved and filter sterilized into the autoclaved media
after it has cooled to room temperature.
3. Complete media 1 (for cultivation of Jurkat, clone E6-1 ATCC® TIB-152TM): 225 mL of
sterile 1x RPMI 1640 with L-glutamine (Corning), 25 mL Fetal bovine serum (FBS)
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(Millipore Sigma), 2.5 mL Penicillin-Streptomycin-Glutamine 100x (Gibco). This
solution is filter sterilized using a 0.2µm vacuum filter (Thermo ScientificTMNalgeneTM
Rapid-FlowTM). The sterilized filtrate referred to as complete media is aliquoted in 10 mL
volumes into sterile 15 mL Falcon® tubes and stored at 4ºC or -20ºC.
4. Complete media 2 (for the cultivation of Molt-4 ATCC® CRL-1582TM): 225 mL of
sterile 1x RPMI 1640 (Gibco), 25 mL of FBS (Millipore Sigma), 2.5 mL PenicillinStreptomycin (Gibco). The complete media is filter sterilized using a 0.2µm vacuum
filter (Thermo ScientificTMNalgeneTM Rapid-FlowTM). The sterilized filtrate referred to as
complete media is aliquoted in 10 mL volumes into sterile 15 mL Falcon tubes® and
stored at 4ºC or -20ºC.
5. All samples of Rhodococcus rhodochrous strain DAP 96273 utilized for this project were
obtained from stocks made by Dr. Kelly Cannon.

2.2 Chemicals and Solutions
2.2.1. Sodium nitroprusside solution
1% stock solution was prepared by dissolving 1g of sodium nitroprusside dihydrate
(Honeywell) in 99 mL of deionized water. The stock solution was kept at 4ºC in the dark and
working solutions were prepared by mixing the stock solution with deionized water in 1:100
ratio and was stable for up to a month with storage at 4ºC in the dark.
2.2.2 Sodium phenate solution
Sodium phenate solution was prepared by dissolving 25g of Phenol (≥ 99.5% GC grade
Sigma -Aldrich) in 800 mL of deionized water, 78 mL of 4N Sodium hydroxide (Sigma-Aldrich)
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was stirred in and deionized water was added in to reach a final volume of 1L. The solution was
kept at 4ºC in the dark and is stable for up to 2 months.
2.2.3 Sodium hypochlorite
Sodium hypochlorite working solution was prepared by mixing 25 mL of commercial
Clorox bleach with deionized water to reach a final volume of 1L. This solution is typically
prepared fresh before an assay but will keep for up to 1 month at 4ºC
2.2.4 Buffer Solutions
The volume of the acid and conjugate base component of all the buffers utilized for this
study were determined using the Michaelis Menten equation. Buffers were utilized for washing
cells, cell lysis, dialysis, purification, protein storage and pH studies.
2.3 Methods
2.3.1 Bacterial cell cultivation
Cells utilized for the study were either obtained from fermentation by either Dr Kelly
Cannon or Dr Maurice de la Croix. In cases where cells weren’t obtained from fermentation in a
bioreactor, 1 mL of stock cells preserved at -80ºC were transferred aseptically to 100 mL of
sterile nutrient broth (BD Difco TM) and incubated at 30ºC in an incubator shaker for 48 hours,
after which the contents were transferred to 1L of YEMEA broth or mR3A broth or spread on
YEMEA plates. Broth samples were incubated at 30ºC in an incubator shaker (New Brunswick
Scientific Edison NJ USA) for 5 days before harvesting by centrifugation at 13,000 rpm for 5
minutes using a Beckman AvantiTM J-25 centrifuge with the JLA-16.250 rotor. When grown on
solid media, cells were grown for 9 days before harvesting by scraping the surface of the agar.
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Figure 7: Cell scraper utilized in the harvest of cells from solid media.

2.3.2 Cell lysis
Induced cells of R. rhodochrous DAP 96253 were suspended in three different lysis
buffers: 25mM Sodium phosphate buffer (PB), 50 mM MOPS or 50 mM Tris-HCl, varying pH
and with or without 5mM 2- mercaptoethanol supplementation. Cell suspensions were made
using a ratio of 1 g of whole cells (packed wet weight) per 1 mL of lysis buffer (w/v) and
vortexed until cells were entirely suspended. Cells were lysed either by high-pressure
homogenization or sonication. High pressure homogenization was performed at 4ºC using an
APV- 1000 (homogenizer) at 700 bar. Sonication was conducted on ice for 20 minutes at 1 sec
on 1 sec off cycling using a Fisher® 550 Sonic Dismembrator [with Minonix incorporated
convertor and a horn with a ½” diameter tip]
Sonicated or homogenized cells were centrifuged for 30 minutes at 13,000 RPM at 4C
using a Beckman AvantiTM J-25 centrifuge with the JA-25-50 rotor or a Beckman CoulterTM
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AllegraTM 64R centrifuge with the Conical C1015 rotor. The centrifugation was repeated three
times recovering the supernatant, termed as the cell free lysate (CFL).
2.3.3 Dialysis
All CFLs containing 2-mercaptoethanol were dialyzed in the following manner. 7 mL of CFL
was loaded into an untreated Spectra/Por 3 dialysis membrane (Standard RC Tubing of 3550
MWCO) and was dialyzed for up to 40 hours with constant stirring at 4C against 300 mL of
dialysis buffer. (50mM PB, 1.5% glycerol, 1% MgSO4.7H20, and 5mM 2-mercaptoethanol).
2.3.4 Anion exchange chromatography
Anion exchange chromatography (AEX) was performed using a GE AKTAExplorerTM
model 100 (Amersham Pharmacia, Piscataway, NJ) fast protein liquid chromatography (FPLC)
controlled using the UNICORN 5.11 application. Protein peaks were detected using GE UV-900
detector at wavelength UV280, protein elutions were collected using the GE Frac 950
autosampler. AEX was executed using a HitrapQ HP packed with 34µm Q Sepharose
ammonium anion exchange resin. 50 mM Tris-HCl, 50 mM MOPS or 25 mM PB at several pHs
were evaluated as equilibration buffers. The column was equilibrated using 5 column volumes of
equilibration buffer at a flowrate of 1 mL per minute, after which the dialyzed sample, diluted at
a 1:1 ratio to a final volume of 10 mL using the equilibration buffer was loaded onto the AEX
column at a flowrate of 0.5 mL per minute. Unbound proteins were washed from the column
using 4 to 5 column volumes of equilibration buffer or until a baseline was reestablished. Elution
of bound proteins was accomplished using a 1M NaCl linear gradient in assigned volumes of 5
mL at a flow rate of 1 mL/minute. These collected volumes were analyzed for ASNase and
GLNase activity . Samples exhibiting enzyme activity were pooled together and purified further
using size exclusion chromatography.
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2.3.5 Size exclusion chromatography
Size exclusion chromatography (SEC) was conducted post AEX. This process was
executed using a GE AKTAExplorerTM model 100 (Amersham Pharmacia, Piscataway, NJ) fast
protein liquid chromatography (FPLC) controlled using the UNICORN app 5.11 application,
employing a HiprepTM 16/60 SephacrylTM S500 HR, a propylene column packed with dextran
acrylamide particle platform allyl dextran and N, N methylenebisacrylamide. The column was
first equilibrated using 2 column volumes of PB at pH 7.6 at a flow rate of 0.5 mL/minute,
partially purified protein samples were then loaded onto the column at a flow rate of 0.5
mL/minute and the increasingly purified proteins were collected using the FRAC950 in 5 mL
fractions. The fractions were analyzed for ASNase and GLNase activity.
2.3.6 ASNase and GLNase activity
ASNase and GLNAse were quantified using 1000ppm ASN (Sigma Life Science) and
GLN (Sigma) solution (10mg of ASN or GLN dissolved in 10 mL of 25mM PB pH 7.6). 10µL
of CFL or purified protein was reacted with 990µL of ASN or GLN solution for 2 minutes. The
reaction was stopped by the addition of 10µL freshly prepared 2M H2SO4 and vortexed for 1
minute, 10µL of 4N NaOH (Sigma-Aldrich) was added and also vortexed for 1 minute to
neutralize the acid.
The solution was transferred to a clean test tube and the amount of ammonia generated
was determined by a modification of the method by Fawcett and Scott[34]. Colorimetric reagents
were added in this order; 2 mL sodium phenate, 3 mL of sodium nitroprusside and 3 mL of
sodium hypochlorite. The test tubes are vortexed after the addition of each reagent for 1 minute
and incubated at RT in the dark for 30 minutes. The ASNAse and GLNase assay for each sample
was performed in triplicates. 200µL of each reaction solution was loaded into an untreated 96
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well plate (Carplugs/ Evergreen u bottomed) and absorbance was read at a wavelength of 630nm
using a PW Victor 3 V (Wallac1420) plate reader. The amount of ammonia generated was
extrapolated by comparing to an ammonia standard of 0-20 ppm. One unit of ASNase or GLNase
is defined as the amount of enzyme required to convert 1µM of ASN or GLN into 1µM of
aspartic acid or glutamic acid and 1µM of NH3 per minute per mg of protein at RT, at pH 7.6.
2.3.7 NHase activity
NHase activity was determined using 1000ppm Acrylonitrile as the substrate (12.3µL of
acrylonitrile mixed with 10 mL of 25mM PB pH 7.6). 10µL of CFL or purified protein was
stopped by reacted with 990µL of acrylonitrile solution for 2 minutes. The reaction was stopped
by the addition of 10µL freshly prepared 2M H2SO4 and vortexed for 1 minute, 10µL of 4N
NaOH (Sigma-Aldrich) was added and vortexed for 1 minute to neutralize the acid. 1 mL of the
reaction solution is transferred to a clean Eppendorf tube and 10µL of a working solution of
Amidase (Amidase from Pseudomonas aeruginosa ≥ 100 units Sigma-Aldrich, made by mixing
1 part Amidase with 49 parts sterile deionized water) is added to the solution. The tubes were
incubated at 37ºC for 30 minutes.
The solution was transferred to a clean test tube and the amount of ammonia generated
was determined by a modification of the method by Fawcett and Scott[34]. Colorimetric reagents
were added in this order; 2 mL sodium phenate, 3 mL of sodium nitroprusside and 3 mL of
sodium hypochlorite. The test tubes are vortexed after the addition of each reagent for 1 minute
and incubated at RT in the dark for 30 minutes. The NHase assay for each sample was performed
in triplicates. 200µL of each reaction solution was loaded in triplicates into a 96 well u bottomed
plate and absorbance is measured at wavelength of 630nm using a PW Victor 3 V (Wallac1420)
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plate reader. The amount of ammonia generated was extrapolated after color development by
comparing to an ammonia standard of 0-20 ppm.
One unit of NHase is defined as the amount of enzyme required to convert 1µM of
acrylonitrile into 1µM of acrylic acid per minute, per mg of protein at RT, at pH 7.6.
2.3.8 Protein quantification
Proteins obtained from the cell lysis and purification were quantified using the Bradford
or BCA protein quantification assay.
When performing the Bradford protein quantification, A standard protein dilution of 0 to
2000 µg/mL of protein was made using an Albumin standard (Thermo Scientific), multiple
dilutions of the samples to be quantified were also made to fall within the 10 to 200 µg/mL
protein range. 25µL of the protein standard and diluted samples were loaded in triplicates into an
untreated 96 well plate (Carplugs/ Evergreen flat bottomed) and 250µL of the Bradford reagent
(ThermoFisher Scientific) was added to each well and the plate was incubated at RT for 10
minutes. Absorbance was measured at 595nm using a PW Victor 3 V (Wallac1420) plate reader.
With the BCA quantification, a standard protein dilution of 0 to 2000 µg/mL of an
Albumin standard (Thermo Scientific) and multiple dilutions of the samples to be quantified
were also made and loaded in triplicates into an untreated 96 well plate (Carplugs/Evergreen flat
bottomed). 200µL of BCA working solution (49 parts PierceTM protein assay reagent A plus 1part PierceTM protein assay reagent B) was added to each well. The well plate was incubated at
37ºC for 30 minutes to allow for complete color development. Absorbance was measured at
562nm using a PW Victor 3 V (Wallac1420) plate reader. Protein concentration of the samples
were extrapolated by comparing to the standard curve calculated from the standard dilutions.
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2.3.9 Mammalian cell culture
Jurkat, clone E6-1(ATCC® TIB-152TM) and Molt-4 (ATCC® CRL-1582TM), T
lymphoblasts expressing acute T cell leukemia and acute lymphoblastic leukemia respectively,
obtained from ATCC were revived using complete media. All the steps for the revival and
culture of mammalian cells were performed aseptically in a Biosafety cabinet and using 70%
alcohol solution. The vials of mammalian cells obtained from ATCC were brought up to 37ºC
using a water bath. 1 mL of the contents from the vial was transferred to a falcon tube containing
9 mL of complete media which had also been brought up to 37ºC. After very slight agitation to
homogenize the solution, the falcon tube was centrifuged at 120g for 7 minutes using a Beckman
Coulter Allegra® X15R Centrifuge. The supernatant now containing the cryopreservant used for
preservation of cells was discarded and the cells which were in a pellet were resuspended in 2
mL of complete media and transferred to a T25 mammalian cell culture flasks (Corning)
containing 8 mL of complete media. The flask was incubated at 37°C at 5% CO2 saturation in a
Queue Stabiltherm CO2 incubator. After 72 hours of growth, a cell count was performed by
staining 20µL of cells with 20µL of 0.4% Trypan blue solution (Sigma®). 20µL of this
suspension was loaded into Nexcelom cell counting chamber and the cell number and viability
was determined using a Nexcelom Biosciences cellometer® auto 2000 cell viability counter.
This count was performed to determine if the cells are confluent (cell density of 3x106 cells/mL
for Jurkat Clone E6-1 and 2x106 cells/mL for Molt-4). Protein efficacy studies and stock samples
of cells were made after cells were determined to have reached confluence. Stocks were made by
suspending 5x105 cells/mL in freeze media (Complete media supplemented with 5% v/v
Dimethyl sulfoxide (Fisher BioreagentsTM) stored at 4ºC). This suspension was stored in 1 mL
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volumes in cryovials for 1 hour at 4°C, another hour at -20°C and overnight at -80°C. The vials
were then transferred to liquid nitrogen for storage indefinitely.
2.3.10 Molecular weight determination
Samples exhibiting ASNase and GLNase activity were diluted to 10mg/mL of protein
using 2.5µL of NuPAGETM LDS sample buffer (4x), 1µL of NuPAGETM reducing agent (10x)
and deionized water up to a final volume of 15µL. These samples were heat treated at 70ºC for
10 minutes or 95ºC for 5 minutes using a heat block (Benchmark MyBlockTM). These heat
treated samples as well as PageRulerTM plus prestained protein ladder (10 to250 kDa) were
loaded onto a precast NuPAGETM Novex Bis-tris gels. The gel was run employing an SE 600
Ruby system (Amersham Sciences), Invitrogen NuPage® Novex® gel chamber, and NuPage®
Novex® 1x MOPS SDS running buffer, voltage was set to 200V, and power was set to 50W.
After a run time of ̴45 minutes, the protein bands were visualized by staining using Coomassie
brilliant blue staining solution (0.25g Coomassie brilliant blue R-250/ 90 mL of Methanol
(Sigma-Aldrich): deionized water, 1:1 v/v, and 10 mL of glacial acetic acid (Fisher chemical))
overnight and destained by suspending the gel in destaining solution (deionized water/ Methanol
(Sigma-Adrich)/ glacial acetic acid (Fisher chemical) in 50/40/10, v/v/v) for up to 4 hours. Gels
images were captured using a UVP BioDoc-ItTM imaging system.
2.3.11 pH and Thermal stability of protein purification
CFL obtained from induced cells of R. rhodochrous DAP 96253 was purified using AEX
and SEC described above at pH ranging from 6 to 9 to determine the optimum pH for
purification. 25mM sodium phosphate buffer was employed for purifications from pH 6-8 and
25mM Tris HCl buffer was employed for purifications at pH 8 and 9. After determining the
optimum pH for purification, purified protein samples exhibiting stable ASNase and GLNase
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activity were also incubated for 25 hours at pH 3, 4, 5, 6, 7, 7.2, 7.4, 7.6, 8, 9 and 10 to determine
the protein stability at varying pH. 100mM Citrate buffer was employed for pH ranging from 35, 50mM sodium phosphate buffer for pH ranging from 6-8 and Glycine-NaOH for pH 9 and 10.
Post incubation, samples were analyzed for ASNAse and GLNase activity using the method
described above.
Purified protein samples obtained from induced cells of R. rhodochrous DAP 96253
exhibiting stable ASNase and GLNAse activity were also incubated at 4, 10, 15, 25, 30, 37, 42,
and 50ºC. The samples were incubated at these temperatures for up to 60 minutes and assayed
for ASNase and GLNase activity at the 15, 30 and 60-minute timepoints.
2.3.12 Effect of selected chemicals on ASNase and GLNase activity of protein preparations
The purified protein preparation obtained from induced cells of R. rhodochrous DAP
96253 were incubated for 30 minutes with selected chemicals at varying concentrations to
determine their effect on the ASNase and GLNase activity. The effectors tested and the
concentrations are listed in table 1. The sample was incubated for up to 1 hour at RT before the
samples were analyzed for ASNase and GLNase activity.
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Table 1: List of chemicals evaluated for their effect on ASNase and GLNase activity of protein preparation
obtained from induced R. rhodochrous DAP 96253

Name

Concentration
(mM)

1

Zinc chloride (ZnCl2)

7.4

2

Magnesium chloride

4.9

(MgCl2)
3

Silver nitrate (AgNO3)

8.9

4

2- Mercaptoethanol

12.8

5

Iron II sulfate (FeSO4)

3.6

6

Copper sulfate (CuSO4)

4.0

7

Hydrogen peroxide (H2O2)

29.4

8

Ammonium persulfate

4.4

((NH4)2S2O8)
9

Calcium chloride (CaCl2)

11.0

10

Cobalt chloride (CoCl2)

1.0

11

Sodium phosphate buffer

50.0

12

Manganese sulfate (MnSO4)

1.0

2.3.12 Stability of ASNase in human serum
O.5 mL of purified protein preparation obtained from induced cells of R. rhodochrous
DAP 96253 was mixed with 2.5 mL of sterile human serum (Sigma) to a obtain a final enzyme
concentration of 50 IU/mL and the mixture was incubated at 37ºC. ASNase activity was
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determined every 5 hours for up to 55 hours to determine the level of deterioration of ASNase in
human serum.
2.3.13 Endotoxin determination
The endotoxin concentrations of CFL and purified protein preparations obtained from R.
rhodochrous DAP 96253 were determined using a Charles River LAL Endosafe Endochrome
kit. A standard was prepared using lyophilized E. coli 055: B5 endotoxin ranging from 50
endotoxin units (EU) per mL to 0.005 EU/mL. Samples analyzed for endotoxins included R.
rhodochrous DAP 96253 CFL, CFL purified using AEX and CFL purified AEX and SEC. A
positive control (E. coli K12 CFL prepared using the same method for lysis employed with R.
rhodochrous DAP 96253) was also tested. 100µL of standards and samples were loaded in
duplicates into a pyrogen free 96 well plate (Endosafe®) and incubated at 37ºC for 5 minutes.
100µL of reconstituted lyophilized limulus amebocyte lysate was added to each well, and the
intensity of color formation based on the concentration of endotoxin in samples and standards
was measured using a PW Victor 3 V (Wallac1420) multiplate reader at a wavelength of 405nm
2.3.14 Efficacy of protein preparation against leukemia expressing cell lines
Jurkat Clone E6-1 and Molt-4 were the two-leukemia expressing cell lines utilized for
this test. Approximately 1.2 x104 cells/well for Jurkat E6-1 cells and 3.0 x105 cells/ well for the
Molt-4 were subcultured in sterile 96 well plate in duplicates and treated with varying amounts
of the purified protein preparation obtained from induced cells of R. rhodochrous DAP 96253
(table 2) and appropriate controls were performed using purification buffers. The inoculated well
plate was incubated at 37°C in Queue Stabiltherm CO2 incubator at 5% CO2 saturation and 37°C
for up to 96 hours. Cell count and viability were determined at 24-hour timepoints by staining

28
using 0.4% trypan blue solution (Sigma®) and counting using a Nexcelom Bioscience
cellometer® auto 2000 viability counter.
Table 2: Depicts the dose, volume, ASNase and GLNase concentration (IU/mL and IU/mg) of the protein
preparations utilized for the leukemia expressing cell line treatment.

Jurkat E6-1 cell line
Dose

Molt-4 cell line

Volume

ASNase

GLNase

ASNase

GLNase

ASNase

GLNase

ASNase

GLNase

(µL)

(IU/mL)

(IU/mL)

(IU/mg)

(IU/mg)

(IU/mL)

(IU/mL)

(IU/mg)

(IU/mg)

Control

100 PB

0

0

0

0

0

0

0

0

1x

5

27

125

22

102

60

9

74.8

7

2x

0

54

250

44

203

119.5

17

149.4 14

3x

5

81

375

61

305

239

26

299

4x

00

108

500

81

407

478

35

597.5 28

21

29
3

RESULTS

3.1 Enzyme profile of R. rhodochrous DAP 96253 in different media
After growth of and induction of R. rhodochrous DAP 96253 in mR3A broth, YEMEA
broth or on YEMEA plates incorporating Urea and Cobalt II chloride, cells grown in broth were
harvested by centrifugation and cells grown on agar were harvested by carefully scraping the
agar. These whole cells were analyzed for a number of select enzymes. The enzyme activities are
defined in international units per mg of cell dry weight (IU/mg CDW). One international unit is
the amount of enzyme required to catalyze the conversion of one µmole of the substrate into one
µmole of the product per minute per mg of cell dry weight at pH 7.6, at RT.

Table 3: Enzyme activity of induced cells of R. rhodochrous DAP 96253 grown on YEMEA plates

Enzyme

NHase

ASNase

GLNase

activity

ACC

Cyanidase

Urease

deaminase

(IU/mgCDW)

Induced with

412.5±34.7 4.7±1.4

22.8±2.2

2.1±0.1

11.2±0.3

10.6±0.3

3.1±0.1

0.1

0.9± 0.1

0.1

5.0±0.6

Urea and
Cobalt II
chloride
W/O Urea
and Cobalt II
chloride

0.1
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Table 4: Enzyme activity of induced cells of R. rhodochrous DAP 96253 grown in YEMEA broth

Enzyme

NHase

ASNase

GLNase

activity

ACC

Cyanidase Urease

deaminase

(IU/mgCDW)

491.5±56.7 9.5±2.5

17.5±3.2 3.8±0.7

3.9±0.1

ND

Table 5: Enzyme activity of induced cells of R. rhodochrous DAP 96253 grown in mR3A media

Enzyme
activity

NHase

ASNase

GLNase

ACC

Cyanidase Urease

deaminase

(IU/mgCDW)

352.9±44.6 16.4±0.4 22.8±2.2 ND

ND

ND

In the development of a purification scheme to obtain an ASNase/ GLNase preparation that
was reproducible, a number of variables were explored such as the impact of the method of lysis,
use of reducing agents and duration of dialysis. The goal was to develop a method of purification
that resulted in reproducible protein preparations exhibiting stable ASNase and GLNase activity.
The impact of the method employed for lysis, reducing agents (2-mercaptoethanol) and the
duration of dialysis was investigated on the ASNase and GLNase activity of the purified protein.
In all cases of analysis, induced cells were lysed and purified, and the variables were
incorporated and compared to negative controls. Samples from the lysis and purification were
analyzed for ASNase and GLNase activity using the modified Fawcett and Scott method[34].
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3.2 Cell lysis exploring homogenization and sonication
After growth and induction, cells of R. rhodochrous DAP 96253 were suspended in lysis
buffer and cells were lysed using homogenization and sonication. The cell free lysate obtained
from both processes were purified using AEX and the fractions obtained analyzed for ASNase
and GLNase activity.

Table 6: Compares the ASNase and GLNase activity of CFL and CFL purified using AEX. The CFL were
obtained using 2 different means of cell lysis.

Homogenization

CFL

NHase

ASNase

(mg/mL)

(mg/mL) (mg/mL) (mg/mL)

(mg/mL) (mg/mL)

33.1± 2.9

0.0

136.3 ±

156.7 ±

30.2

2.6

204.5 ±

324.6 ±

27.6

35.2

AEX 229.2 ± 45.6

0.0

GLNase

Sonication

1.4 ± 0.2

0.0

NHase

ND

ND

ASNase

GLNase
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Figure 8: Comparison of the methods of homogenization and sonication for cell lysis and their impact on
ASNase/GLNase activity

3.3 Cell lysis w/wo the incorporation of 2-mercaptoethanol
Having established the superiority of sonication as the better means of cell lysis, the
effect of a reducing agent, specifically 2- mercaptoethanol on the ASNase and GLNase activity
was investigated. 2-mercaptoethanol was incorporated into the lysis buffer in up to a 5mM
concentration and cells were lysed and purified using AEX. Both the CFL and fractions obtained
from the purification were analyzed for ASNase and GLNase activity.
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Table 7: Compares the ASNase activity of samples obtained from lysis incorporating 2-mercaptoethanol
and Samples lysed without 2-mercaptoethanol

2-mercaptoethanol
PRESENT

ABSENT

ASNase (mg/mL)

ASNase (mg/mL)

CFL

443.8 ± 24.6

12.4 ± 1.3

AEX

1280 ± 38.9

39.6 ± 2.8

1400
1200
1000
800
600
400
200
0
ASNase(mg/mL)

ASNase(mg/mL)

W βME

WO βME
CFL

AEX

Figure 9: Evaluation of the effect of incorporating βME into the lysis process on ASNase activity of samples
obtained from induced cells of R. rhodochrous DAP 96253
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3.4 Effect of the duration of dialysis on ASNase activity
Protein dialysis employing a dialysis membrane with a 3.5kDa molecular weight cutoff
was utilized to get rid of the 2-mercaptoethanol post cell lysis. The duration of the dialysis and
its impact on the stability of the ASNase was also investigated. Samples were dialyzed for up to
40 hours and analyzed for ASNase activity. These dialyzed samples were also purified using
AEX and analyzed for ASNase activity too.

Table 8: Comparison of ASNase activity of CFL and AEX purified samples obtained after varying lengths
of dialysis.

No dialysis

24 hour Dialysis

40 hour Dialysis

ASNAse (mg/mL)

ASNase(mg/mL)

ASNase (mg/mL)

CFL

12.7 ± 2.9

38.4 ± 3.8

65.9 ± 4.8

AEX

49.3 ± 7.8

163 ± 5.6

682 ± 87.6
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Figure 10: Evaluation of the duration of dialysis on the ASNase activity of CFL and protein purification
obtained from induced cells of R. rhodochrous DAP 96253.

3.5 Determination of optimum pH to obtain protein preparation exhibiting stable ASNase
activity from induced cells of R. rhodochrous DAP 96253.
With the determination of the sonication as the better of the two means of cell lysis, the
incorporation of 2-merceptoethanol at 5mM concentration into the lysis buffer as well as dialysis
for up to 40 hours significantly improved the ASNase and GLNase activity of the CFL obtained
from induced cells of R. rhodochrous DAP 96253 and the subsequently purified CFL via AEX
also exhibited improved ASNase and GLNase activity. Purifications of ASNase were then
performed at pH 6, 7, 8, and 9 to determine the optimum pH for the puifirication process. 25mM
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PB was selected for pH ranging from 6 to 8 and 25mM Tris-HCl was selected for pH 9. The lysis
process incorporated 2-mercaptoethanol up to 5mM and sonication was utilized for cell lysis and
the CFL was dialysed for up to 40 hours before AEX. SEC was investigated and also
incorporated into the purofication process to obtain a purer, more active protein.

Table 9: Comparison of ASNase activity of protein preparation lysed and purified at pH 6, 7, 8 and 9

pH 6.0

pH 7.0

pH 8.0

pH 9.0

ASNase (IU/mg)

ASNase (IU/mg)

ASNase (IU/mg)

ASNase (IU/mg)

CFL

12.9 ± 3.7

32.6 ± 5.3

24.6 ± 3.8

10.3 ± 4.3

AEX

123.6 ± 15.8

200.6 ± 16.8

49.75 ± 4.9

5.2 ± 1.8

SEC

0.1

342.25 ± 13.7

151.25 ± 21.5

0.1
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Figure 11: Comparison of ASNase activity of protein preparations obtained from induced cells of R.
rhodochrous DAP 96253 lysed and purified using AEX and SEC at varying pHs.

,3.6 Protein purification incorporating sonication as a means of lysis, 2-mercaptoethanol
into the lysis buffer, dialysis for 40 hours and AEX and SEC at pH 7.6
Under the conditions employed, it was established based on these results that the optimum
pH for purification lay around pH 7.0. Etna Sanchez investigated the optimum pH, focusing on
pH 6.8, 7.0, 7.2, 7.4, 7.8, and 8.0. The data she obtained allowed for us to conclude that
purification at pH 7.6 showed the highest and most stable ASNase and GLNase activity.
Subsequent purifications were then performed at pH 7.6, incorporating 5mM mercaptoethanol
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into the lysis buffer and using sonification as a means of cell lysis. Size exclusion
chromatography was also incorporated into the purification process because the purer protein
obtained showed improved ASNase and GLNase activity. Using the data garnered thus far, a
purification using AEX and SEC was performed at pH 7.6, incorporating 5mM 2-mercapethanol
into the lysis buffer and utilizing sonication as the means of cell lysis and the elution obtained
was analyzed for ASNase and GLNase activity.

Table 10: ASNase and GLNase activity of protein preparation obtained from the purification of CFL
obtained from induced cells of R. rhodochrous DAP 96253. The cells were lysed using PB incorporating
5mM βME and sonication and the purification process involved AEX and SEC

Total activity

Specific activty

(IU/mL)

(IU/mg)

Fold purification

Percentage yield

ASNase

GLNase

ASNase

GLNase

ASNase

GLNase

ASNase

GLNase

CFL

2308

3107

136

183

1

1

100

100

AEX

2008

3032

386

583

4

3

87

98

SEC

1790

2607

1492

2173

23

20

78

84

3.7 Protein characterization (Temperature)
The purification obtained using the variables analyzed above was characterized to
determine the stability of the protein preparation at temperature range of 4, 10, 15, 25, 30, 37, 42
and 50℃. The protein prepration was aliquoted into small fractions and incubated at these
temperatures for up to an hour. The ASNase and GLNase activity of the samples were analyzed
peridoically as a measure of protein stability.
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Table 11: Shows the varying ASNase/ GLNase activity of the purified protein obtained from induced cells
of R. rhodochrous DAP 96253 after incubation for 15 minutes at varying temperatures.

Temperature (℃)

ASNase (IU/mg)

GLNase (IU/mg)

4

251.4 ± 33.5

999.5 ± 23.2

10

190.9 ± 31.2

878.47 ± 28.8

15

105.23 ± 16.95

219.96 ± 5.1

25

244.87 ± 29.01

290.1 ± 12.39

30

420.27 ± 20.82

873.64 ± 53.1

37

466.7 ± 12.58

1291.22 ± 219.6

42

303.25 ± 27.63

518.74 ± 21.76

50

223.4 ± 2.79

470.18 ± 58.8

Table 12: Shows the varying ASNase/ GLNase activity of the purified protein obtained from induced cells
of R. rhodochrous DAP 96253 after incubation for 30 minutes at varying temperatures.

Temperature (℃)

ASNase (IU/mL)

GLNase (IU/mL)

4

552.4 ± 73.7

1122.5± 48.64

10

498.2 ± 87.28

1376.58 ± 92.78

15

554.04 ± 3.1

766.94 ± 61.26

25

572.14 ± 7.4

775.4 ± 68.9

30

590.03 ± 90.74

853.56 ± 88.48

37

632.15 ± 47.2

1454.6 ± 135.7

42

488.2 ± 59.9

776.5 ± 47.7

40
50

416.61 ± 78.66

475.1 ± 31.86

Table 13: Shows the varying ASNase/ GLNase activity of the purified protein obtained from induced cells
of R. rhodochrous DAP 96253 after incubation for 60 minutes at varying temperatures.

Temperature ℃)

ASNase (IU/mL)

GLNase (IU/mL)

4

417.14 ± 11.7

849.23 ± 147.9

10

191.1 ± 8.9

477.34 ± 78.8

15

292. 82 ± 2.81

1230.71 ± 68.9

25

349.33 ± 25.7

1340.41± 58.64

30

368.9 ± 21.8

2016.6 ± 10.57

37

406.84 ± 4.96

2154.59± 251.34

42

196.7 ± 40.1

1299.52 ± 8.91

50

177.3 ± 28.7

640.1 ± 15.95
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Figure 12: Shows stability of ASNase purified from induced cells of R. rhodochrous DAP 96253 at varying
temperatures ranging from 4℃ to 50℃

42

GLNase (IU/mg)
3000

2500

2000

1500

1000

500

0
3

8

13

18

15 minutes

23

28

30 minutes

33

38

43

48

53

60 minutes

Figure 13: Shows stability of ASNase purified from induced cells of R. rhodochrous DAP 96253 at varying
temperatures ranging from 4℃ to 50℃

3.8 Protein characterization (pH)
The purification obtained using the variables analyzed above was characterized to
determine the stability of the protein preparation at pH range of 3, 4, 5, 6, 7, 8, 9, and 10. pH 7.2,
7.4, 7.6, and 7.8 were also analysed because previous studies showed the protein to be most
stable at pH ranging frrom 7 to 8. The protein prepration was aliquoted into small fractions and
incubated at these pHs for up to 25 hours. The ASNase and GLNase activity of the samples were
analyzed as a measure of protein stability.
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Table 14: Shows the varying ASNase/ GLNase activity of the purified protein after incubation at varying
pHs for 25 hours

pH

ASNase (IU/mg)

GLNase (IU/mg)

3

195 ± 34

1199 ± 148

4

497 ± 62

1667 ± 257

5

553 ± 99

1910 ± 107

6

803 ± 77

2347 ± 115

7

966 ± 18

2502 ± 148

7.2

967 ± 20

2505 ± 145

7.4

1226 ± 133

2654 ± 133

7.6

2491 ± 115

3995 ± 86

7.8

762 ± 28

2310 ± 54

8

143 ± 20

1753 ± 258

9

48 ± 10

1173 ± 200

10

0

44 ± 11
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Figure 14: Shows the relative ASNase and GLNase activity of protein preparation purified from induced
cells of R. rhodochrous DAP 96253 at pH ranging from 3 to 10 with optimum ASNase and GLNase activity
observed at pH 7.6

3.9 Molecular weight determination of the purified protein sample
Samples from the lysis, AEX and SEC were analyzed for purity and molecular weight
determination using an SDS-PAGE. Samples were loaded on the gel and after the run was
completed, the gels were stained using Coomassie brilliant blue dye and destained. The gel
image was developed and analyzed to determine protein purity with each successive purification.
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a
MWC.

1

b
2

MWC.

1

Figure 15: SDS- PAGE for protein preparation from induced cells of R. rhodochrous DAP 96253. (a)
shows the CFL in lane 1 and the AEX fraction in lane 2. (b) shows protein bands from SEC fraction with
ASNase and GLNase activity.

3.10 Stability of protein preparation in sterile human serum
The purified protein samples were incubated in sterile human serum at a 50 IU/ml
concentration and analyzed for ASNase activity using the modified Fawcett and Scott method
periodically until a 50% reduction in initial enzyme activity had been determined.
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Table 15: Demonstrates the stability of ASNAse activity over time in sterile human serum

Time (hours)

ASNasse (IU/mL)

0

50.35 ± 0.5

5

48.34 ± 0.3

10

42.8 ± 1.7

12

39.27 ± 1.2

24

32.73 ± 0.8

29

31.72 ± 0.4

34

30.71 ± 0.6

48

29.2 ± 1.6

53

26.68 ± 0.2

56

23.66± 1.4
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Figure 16: Shows the relative stability of ASNase purified from the induced cells of R. rhodochrous DAP
96253 in sterile human serum over time.

3.11 Determination of endotoxin concentrations of R. rhodochrous DAP 96253 and its
purified products
R. rhodochrous DAP 96253 is a Gram-positive bacteria and therefore lacking in LPS. One
of the proposed benefits to using a an ASNase/ GLNase protein preparation obtianed from R.
rhodochrous DAP discussed earlier is the absence of endotoxins and thus none of the negative
immunological responses associated with Gram-negative bacterial products.
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Table 16: Shows the endotoxin concentration levels of samples obtained from the lysis of induced cells of
R. rhodochrous DAP 96253 and from the purification using AEX and SEC as well as an endotoxin control
using E. coli strain K12

Sample

Endotoxin concentration (EU/mL)

R. rhodochrous DAP 96253 CFL

4.20 ± 0.67

R. rhodocrous DAP 96253 CFL(

21.01 ± 2.43

pruified using AEX)
R. rhodochrous DAP 96253 CFL

107.63 ± 11.72

(purified using AEX and SEC)
E. coli K12 CFL

3239.68 ± 95.86
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Figure 17: Comparison of the endotoxin levels of the CFL obtained from induced cells of R. rhodochrous
DAP 96253 before and after purification using just AEX and AEX and CFL and the CFL obtained from E.
coli K12

3.12 Substrate affinity and maximal velocity of protein preparation.
The substrate affinity of the protein preparation exhibiting stable ASNase and GLNase
activity was determined using the substrate ASN and GLN in varying concentrations. This study
was performed to determine how effective the protein preparation will be as a treatment measure
for ALL. Substrate concentrations analyzed ranged from 0.05 to 26.6mM. The substrate affinity
(Km) for ASN was determined based on the graph below (fig 17) to be 0.0136mM and the
maximal velocity (Vmax)was determined to be 5µmoles/ minute.
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Figure 18: Line-Weaver Burke plot utilized in the determination of substrate affinity and maximal velocity
for ASN of the protein preparation obtained from induced cells of R. rhodochrous DAP 96253 exhibiting
ASNAse activity.

The Km for GLN was determined to be signficantly higher than the Km observed for ASN at
0.85mM and a Vmax of 61.3µmoles per minute.
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Figure 19: Line-Weaver Burke plot utilized in the determination of substrate affinity and maximal velocity
for GLN of the protein preparation obtained from induced cells of R. rhodochrous DAP 96253 exhibiting
GLNAse activity.

3.13 Effect of selected chemicals on ASNase activity of protein preparations purified from
induced cells of R. rhodochrous DAP 96253
The effect of selected chemical substances in varying concentrations (table 1) was
evaluated. The effect of some of these chemicals had already been evaluated in other studies and
comparisons were made.
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Table 17: Shows the ASNase activities of the untreated purification and samples treated with selected
chemicals to demonstrate the effect of these chemicals on the purified protein.

Name

ASNase activity
(IU/mg)

1

Untreated enzyme

1219.35 ± 24.38

2

Zinc chloride (ZnCl2)

914.51 ± 14.63

3

Magnesium chloride (MgCl2)

341.42 ± 48.77

4

Silver nitrate (AgNO3)

524.32 ± 12.32

5

2- Mercaptoethanol (βME)

951.09 ± 19.75

6

Iron II sulfate (FeSO4)

1560.77 ± 32.92

7

Copper sulfate (CuSO4)

158.51 ± 3.65

8

Hydrogen peroxide (H2O2)

877.89 ± 17.07

9

Ammonium persulfate

1024.25 ± 20.97

((NH4)2S2O8)
10

Calcium chloride (CaCl2)

829.16 ± 11.94

11

Cobalt chloride (CoCl2)

755.99 ± 13.95

12

Manganese sulfate (MnSO4)

963.29 ± 13.66

13

Sodium phosphate buffer

1877.80 ± 30.48
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Figure 20: Evaluation of the effect of selected chemicals on the ASNase activity of protein preparation
purified from induced cells of R. rhodochrous DAP 96253

3.14 The effect of protein preparations exhibiting ASNase and GLNase activity on
leukemia expressing cell lines
Having determined that stability of the purified protein preparation obtained from
induced cells of R. rhodochrous DAP 96253 in sterile human serum, at varying pHs,
temperatures, the substrate affinity with ASN and GLN and the maximal velocities, the purified
samples were utilized in varying doses to treat leukemia expressing cells. The setup was
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performed in sterile well plates and treated in doses varying from 1x to 4x with controls
incorporating up to 100µL of sterile purification buffers (Table 2). The rate of cell growth, death
or survivability was determined by staining cell samples with trypan blue solution and counting
using a nexcelom cell counter every 24 hours post incubation. After 96 hours, the cell count was
discontinued, and images of the wells were taken at 100x magnification using an inverted
icroscope.

Figure 21: a: Jurkat E6-1 cells shortly after incubation at a concentration of 1x105 cells/mL in complete media. b:
depicts the increased cell density after 72 hours of incubation demonstrating the typical clusters observed with the
Jurkat E6-1 cell line. Image of cells in a culture flask was observed using an inverted microscope at 1000x
magnification
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Figure 22: Molt-4 cells shortly after incubation in complete media. b; depicts the increased cell density after 72
hours of incubation. Image was observed using an inverted microscope at 10000x magnification.
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Figure 23: Depiction of the views observed using the Nexcelom Bioscience cellometer® auto 2000 viability counter.
a; describes the cell number and b; depicts the cells that are viable and still capable of replicating as green and
non-viable cells as red.
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Figure 24: Demonstrates the retardation of Jurkat E6-1 cell viability by the protein preparation obtained
from induced cells of R. rhodochrous DAP 96253. Jurkat E6-1 cell viability reduces over time and
increased protein dose.
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Figure 25: Depicts the cytotoxicity of the purified protein obtained from induced cells of R. rhodochrous
DAP 96253 against the Jurkat E6-1 cell line over a 96-hour time period.
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Figure 26: Control setup created by treating Jurkat E6-1 cells with just 100µL of purification buffer. The
well was incubated for up to 96 hours with 24-hour periodic cell counts and this image was captured using
an inverted microscope.

60

Figure 27: Ix treatment setup demonstrating fewer Jurkat E6-1 cell clusters and reduced cluster size with
treatment using the lowest tested dose of purified protein obtained from induced cells of R. rhodochrous
DAP 96253.
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Figure 28: 2x treatment setup demonstrating much smaller Jurkat E6-1 cell clusters with treatment using
the purified protein obtained from induced cells of R. rhodochrous DAP 96253.
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Figure 29: 3x treatment setup demonstrating much smaller and less tightly packed Jurkat E6-1 cell clusters
with treatment using the purified protein obtained from induced cells of R. rhodochrous DAP 96253.
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Figure 30: 4x treatment setup demonstrating complete absence of the typical Jurkat E6-1 cell clusters with
treatment using the purified protein obtained from induced cells of R. rhodochrous DAP 96253.
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Figure 31: Demonstrating the IC50 of the protein preparation obtained from induced cells of R.
rhodochrous DAP 96253 utilized in the treatment of Jurkat E6-1 cells

The IC50 of the protein preparation purified using AEX and SEC and obtained from
induced cells of R. rhodochrous DAP 96253 against Jurkat E6-1 cells expressing acute leukemia
was determined to be 0.123 IU/mg.
The entire process was repeated utilizing a different cell line, Molt-4 cell line expressing
ALL was utilized in a similar protein setup using different protein concentrations detailed in
table 2 above.
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Figure 32: Demonstrates the effect on Molt-4 cell viability of the protein preparation obtained from
induced cells of R. rhodochrous DAP 96253. Jurkat E6-1 cell viability reduces over time and increased
protein dose.
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Figure 33: Depicts the cytotoxicity of the purified protein obtained from induced cells of R. rhodochrous
DAP 96253 against the Molt-4 cell line over a 96-hour time period.
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Figure 34: Control setup created by treating Molt-4 cells with just the purification buffer demonstrating the
robust cell density. Image was captured after 96 hours of incubation using an inverted microscope
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Figure 35: Ix protein treatment setup utilizing purified protein obtained from induced cells of R.
rhodochrous DAP 96253 demonstrating reduced Molt-4 cell density when compared to the untreated
control
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Figure 36: 2x Protein treatment setup obtained from induced cells of R. rhodochrous DAP 96253. The
image demonstrates a significant reduction in cell number after 96 hours of incubation.
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Figure 37: 3x Protein treatment setup obtained from induced cells of R. rhodochrous DAP 96253. The
image demonstrates a significant reduction in cell number after 96 hours of incubation.
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Figure 38: 4x Protein treatment setup obtained from induced cells of R. rhodochrous DAP 96253. The
image demonstrates a complete absence of cells after 96 hours of incubation.
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Figure 39: Demonstrating the IC50 of the protein preparation obtained from induced cells of R.
rhodochrous DAP 96253 utilized in the treatment of Molt-4 cells

The IC50 of the purified protein preparation obtained from the induced cells of R.
rhodochrous DAP 96253 when utilized in the treatment of Molt-4 cell line expressing ALL was
determined to be 1.982 IU/mg.
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4

DISCUSSIONS

4.1 Enzyme production on varying induction media
R. rhodochrous DAP 96253 enzyme activity on varying induction media were
investigated. All the media investigated incorporated Urea and Cobalt II chloride. Previous
studies conducted in Dr G. E. Pierce’s laboratory at Georgia State University suggests a massive
increase in the production of the NHase enzyme specifically and an increase in the production of
enzymes such as ASNase and GLNase with the incorporation of Urea and Cobalt II chloride into
the growth media. Comparatively, R. rhodochrous DAP 96253 grown on YEMEA not
incorporating Urea and Cobalt II chloride shows no detectable ASNase or GLNase activity and
very low NHase activity (Table 3). This data suggests that induction to upregulate the production
of ASNase and GLNase is vital to obtain a stable protein preparation. The cells utilized for this
study were obtained via fermentation conducted by Dr. K. Cannon or Dr. M. de la Croix or
induced using the media listed above. After growth and induction, the cells are harvested,
typically by centrifugation at 4℃ for about 10 minutes at speeds between 10,000 to 13,000rpm
for cells cultivated and induced in broth and scraped using a cell scraper when the cells are
grown on solid agar (fig 7). The harvested cells are typically utilized immediately after the
harvest is complete or otherwise stored in sterile 50mL Falcon® tubes at 4℃ until the
commencement of the purification process.
4.2 Effect of the methodology of cell lysis: homogenization and sonication
To start, the cells are typically suspended in a lysis buffer (see appendix) in a 1:1 ratio
(w/v in g/mL) and then lysed using the homogenization or sonication. When the cells were
homogenized, a minimum volume of 125 mL of the final volume of the cell suspension was
required for proper cell lysis using the APV homogenizer, making small scale studies using
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suspended volumes less than 150 mL impossible. During the lysis process, steps were taken to
keep the suspension at or below 4℃ to protect protein integrity. However, when lysing R.
rhodochrous, pressure around 700 Bar was required which results in the suspension heating up
with successive passes. Typically, the suspension was allowed to cool to 2℃ before resuming
the homogenization process. This cooling process depending on the volume of the suspension
takes anywhere from 30 to 60 minutes per pass resulting in a total lysis period of close to 4
hours. Despite the efforts to keep the suspension cool, the lysis process has been noted to drive
the temperature of the suspension up to 40℃. Subsequent purifications of the CFL obtained from
the homogenization resulted in protein preparations with low ASNase and GLNase activity.
When sonication was explored, the use of the Fisher® 550 Sonic Dismembrator [with Minonix
incorporated convertor and a horn with a ½” diameter tip] allowed for volumes varying from as
little as 10 mL to as much as 100 mL. The suspension sits in ice throughout the lysis process and
the volume of ice can be adjusted as needed. This process allowed for more stable temperature
control during the lysis process. With the one second on one second off pulsing, cell lysis was
typically completed in about 40 minutes, and enzyme analysis of the CFL obtained after
sonication and fractions obtained from the purification process also showed improved ASNase
and GLNase activity (Table 6). Based on the data obtained, sonication was adopted as the
preferred means of cell lysis for induced cells of R. rhodochrous DAP 96253 targeting a
purification with stable ASNase and GLNase activity.
4.3 Cell lysis incorporating 2-mercaptoethanol
The incorporation of a reducing agent into the lysis process for induced cells of R.
rhodochrous DAP 96253 was investigated. Several studies have extoled the virtues of using
reducing agents for protein stabilization [57,99]. When present in high concentrations, proteins
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aggregate, and this aggregation negatively impacts their native conformation and thus their
function.[42]. Proteins typically aggregate around a cystine amino acid. Cystine is an oxidized
dimer formed by a double linkage between two sulfur residues or a disulfide bridge on separate
cysteine units[105]. It is important to note that this dimerization only occurs under oxidative
conditions. To prevent this protein aggregation, reducing agents such as Dithiothrietol (DTT) or
2-mercaptoethanol (βME) are utilized in the cell lysis process. The reducing agents negate the
oxidizing conditions necessary for the dimerization reaction to form the cystine residue around
which proteins aggregate thus preventing protein aggregation and maintaining the protein
structure and function. βME was utilized as the reducing agent of choice. Cells were lysed using
lysis buffer incorporating βME at a 5mM concentration and compared to a cell lysis not
incorporating βME. Enzyme analysis of the CFL obtained using lysis buffer incorporating βME
and the subsequent purification showed ASNase activity about 35 times higher when compared
to CFL and purifications obtained without incorporating a reducing agent into the lysis buffer
(Table 7, Fig 8). This data suggests that a reducing condition induced using a reducing agent is
necessary for the stability of ASNase obtained from induced cells of R. rhodochrous DAP
96253.
4.4 Impact of the duration of dialysis on ASNase activity.
The sample obtained after the lysis of induced cells of R. rhodochrous DAP 96253
utilizing a buffer incorporating βME in up to 5mM concentration was dialyzed. The dialysis
membrane selected for this study had a molecular cutoff weight of 3.5KDa. Samples from the
dialysis membrane were analyzed after 24 and 40 hours for ASNase activity. The utilization of
dialysis as a component of the purification process was explored due to the utilization of
ammonium sulfate for protein precipitation. Ammonium sulfate has been used in varying
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concentrations for the purification process as it significantly increases the hydrophobicity of
proteins and can be used to “salt out” or separate proteins based on hydrophobicity[110]. This
procedure was not adopted as part of the final purification process because one of the products of
the enzyme assay utilized for analysis is ammonia. Samples precipitated using ammonium
sulfate showed a much higher (false positive) ammonia concentration when analyzed. The
dialysis process was adopted to eradicate the ammonium sulfate post precipitation during the
initial stages of the purification process development. Effective ammonium sulfate eradication
usually took up to 48 hours with at least 3 dialysis buffer changes. After dropping the
precipitation using ammonium sulfate, it was also noticed during the purifications that samples
that were dialyzed immediately showed improved ASNase activity post lysis. It was
hypothesized that dialysis concentrated the CFL and increased enzyme activity. This data made it
necessary then to incorporate dialysis into the purification process even if ammonium sulfate
precipitation was not employed and determine how the period of dialysis impacted the ASNase
and GLNase activity. The analysis of the CFL at two timepoints (24 and 40 hours) suggests that
the longer the sample is dialyzed, the more improved the ASNase and GLNase activity recovered
(Table 8, Fig 9). Based on this data, dialysis for up to 40 hours under the conditions used was
incorporated into the purification protocol.
4.5 Optimum purification pH
At the commencement of this project, sample purifications and enzyme assays were
performed at pH 7.2. The impact of purification pH on ASNase activity was investigated. The
pH range investigated include 6, 7, 8 and 9. The resulting ASNase activity from each of the
purifications is detailed in table 9 and figure 10, with the highest ASNase activity observed at pH
7. Investigations into pH ranges between 7 and 8 showed pH 7.6 to be particularly suitable for a
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purification with stable ASNase activity. All the variables highlighted thus far were incorporated
into a purification and the resulting purified fraction showed ASNase and GLNase activity of
1492 IU/mg and 2173 IU/mg respectively.
4.6 Protein characterization (Temperature)
A purification obtained from induced cells of R. rhodochrous DAP 96253 was
characterized to determine its maximal activity and stability at temperatures ranging from 4℃ to
50℃. The results presented in tables 11, 12 and 13 as well as figure 11 and 12 suggest the
ASNase to be stable at all the analyzed temperatures ranging from 4℃ to 50℃ and the highest
activity was observed at human physiological pH (37℃). As this study was performed over a 60minute period and the samples were tested at 15, 30 and 60 minutes timepoint, ASNase activity
at 37℃ was noted to be highest at the 30-minute timepoint but activity declined by 36% when
analyzed at the 60-minute timepoint.
The GLNase activity like the ASNase was determined to be highest at 37℃ but was
significantly more stable for a longer amount of time, with the GLNase activity progressively
increasing from the 15 to 30 to 60-minute timepoint. In both cases, there was a progressive
decline in ASNase and GLNase activity after 37℃. The increased ASNase and GLNAse activity
at human physiological temperature suggest that the protein preparation will be a suitable
treatment option for ALL.
Studies into temperature-based stability of other ASNases showed that a fungal ASNase
isolated from Rhizomucor meihei showed optimum activity at 45℃ but was only stable for 30
minutes[48], ASNases isolated from Streptomyces gulbargensis, S. fradiae NEAE-82 and
Erwinia sp. were noted to possess maximal ASNase activity at 40℃[4,30,11] and an ASNase
sourced from the plant Vigna unguiculata was also observed to possess maximal enzyme activity
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at 40℃[2]. Bacterial ASNases that have been shown to possess maximal activity comparable to
the ASNase isolated from induced cells of R. rhodochrous DAP 96253 include E. coli ASNase,
S. brollosae NEAE-155 ASNase, and Nocardius alba ASNase. Studies performed suggest that
the vast majority of characterized ASNases from bacterial and fungal sources possess optimal
activity north or south of the physiological human temperature[71,72,16,30].
4.7 Protein characterization (pH)
A characterization was also performed on a purification obtained from induced cells of R.
rhodochrous DAP 96253 checking maximal enzyme activity and stability at pH ranging from 3
to 10. The data obtained (Table 14, Fig 13) suggest that the protein is stable for over 25 hours
when incubated at pH ranging from 3 to 10. The maximal enzyme activity of the protein
purification lay between pH 7 and 8. Investigation of pH points 7.2, 7.4, 7.6, 7.8 and 8.0 showed
the pH with maximal enzyme activity to be pH 7.6. These data are supported by previous
purification studies. It is noteworthy that at physiological pH, the purified protein exhibited
about 50% less ASNase and 66% less GLNase activity. These numbers however were
significantly higher than the activity observed at pH below 7 or above 8. This suggests therefore
that at physiological pH, the protein preparation will still serve as a suitable therapeutic against
ALL.
ASNases obtained from Streptomyces noursei, S. parvulus, S. ginsengisoli and Bacillus
subtilis all had maximal ASNase activity close to the activity observed with the purification from
induced cells of R. rhodochrous DAP 96253 at pH 7.5[23,102,51]. In most other characterized
ASNases such as ASNase isolated from Phaseolus vulgaris seeds[76], as well as ASNase
isolated from S. thermoluteus and B. licheniformis optimal pH for ASNase activity was observed

79
at pH 8 and above and ASNase sourced from E. coli has been demonstrated to possess maximal
enzyme activity between pH 6 to 8 and stability from pH 5.5 to pH 9.[45,67,78].
4.8 Molecular weight determination of the purified protein sample
After cell lysis, anion exchange and size exclusion chromatography, samples from each
step of the purification process containing a total of 10µg of protein was loaded on a premade 412% polyacrylamide gel according to the method detailed above. After destaining the gel, the
purest sample observed in figure 14 above suggests that the protein exhibiting ASNAse and
GLNase activity is a multimeric protein of approximately 123 kDa comprising subunits of ̴72, ̴28
and ̴23 kDa. It is noteworthy that previous studies of purified NHase obtained from induced cells
of R. rhodochrous DAP 96253 also show protein bands in the 28 and 23 kDa location on an SDS
PAGE. This has led to the conclusion that either the NHase obtained from purified cells of R.
rhodochrous DAP 96253 possess unique ASNase and GLNAse activity or induced cells of R.
rhodochrous DAP 96253 produced so much NHase, that NHase is present in the purified
preparation exhibiting ASNase and GLNase activity.
When compared to other characterized ASNases, there were distinct differences. Studies
report that Gram-negative bacterial ASNases are typically homo-tetrameric with subunits around
the 33 and 36.5 kDa and a native size of ̴146 kDa. More specifically, recombinant ASNase
isolated from E. coli was found to be ̴150 kDa, ASNase isolated from Pseudomonas stutzeri MB405 and Thermus thermophilus when run on an SDS PAGE was shown to have subunits about 33
kDa[89,69,101].
Gram-positive bacterial ASNase subunits on the other hand have been showed to be ̴85
kDa in the case of S. gulbargensis, and a 144.4 kDa homotetramer in Pectobacterium
carotovorum MTCC 1428[4,61].
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4.9 Stability of protein preparation in sterile human serum
The results obtained from the studies performed on the stability of the protein preparation
measured the ASNase activity over a specified amount of time. The studies were performed until
the ASNase activity dipped below the 50% of the initial activity. The data obtained shown in
Table15 and Fig 15 suggests that the Rhodococcal ASNase is significantly stable in human
serum, losing 50% of its initial activity after incubation for over 50 hours at 37℃.
A comparison was made to a similar study performed on ASNase isolated from
Enterobacter cloacae and this ASNase was demonstrated to possess a half-life of 39 hours[49].
When compared to currently approved ASNases on the market, E. coli ASNase was found to
possess a halflife of 8 to 30 hours after injection intravenously and E. chryansthemi ASNase was
found to be stable for only 16 hours after injection intramuscularly[111].
4.10 Endotoxin levels of the protein products of induced cells of R. rhodochrous DAP 96253
The currently approved ASNases are sourced from E. coli and E. chrysanthemi. Both
organisms are lipopolysaccharide (LPS) possessing Gram-negative organisms. Products sourced
from Gram-negative organisms utilized for therapeutic go through an expensive cleanup process
to remove bacterial LPS[68]. The effectiveness of this cleanup process however is debatable as
several side effects associated with the use of these products have also been tied to the
immunological response to the presence of LPS.
It was predicted that as a Gram-positive organism, the products obtained from induced
cells of R. rhodochrous DAP 96253 should be endotoxin free. This confers the benefit of
reduced production costs as the expense tied with endotoxin cleanup of products obtained from
Gram-negative organism is circumvented, and the side effects associated with the use of
contaminated Gram-negative bacterial products are avoided all together.
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The CFL and purified products obtained from induced cells of R. rhodochrous DAP
96253 were analyzed for endotoxin concentration at varying levels of the purification process.
The results of the analysis are shown in Table 16 and Fig 16. The data obtained suggests that the
purest sample obtained from R. rhodochrous DAP 96253 showed the highest endotoxin
concentration. This concentration however was found to be 30 times lower than the endotoxin
concentration present in an E. coli K12 control utilized for the study. The data also suggests that
with successive purifications, the endotoxin levels of the purified sample from R. rhodochrous
DAP 96253 spiked. An analysis of the column utilized for the purification process showed that
the column was not endotoxin free and could well be responsible for contaminating the purified
sample. A direct comparison of the CFL obtained from induced cells of R. rhodochrous DAP
96253 and an E. coli K12 control showed that the Rhodococcal sample had an endotoxin
concentration 771 times lower than the E. coli sample. Evidence from the study suggests that the
endotoxin present in the protein preparation was introduced from an external source and not from
the R. rhodochrous. It is safe therefore to state that an ASNase sourced from R. rhodochrous
would be preferable for cancer therapy.
4.11 Km and Vmax for ASN and GLN by protein preparation obtained from induced cells of
R. rhodochrous DAP 96253
Analysis of the substrate affinity utilizing ASN and GLN was performed using purified
protein obtained from induced cells of R. rhodochrous DAP 96253 exhibiting stable ASNase and
GLNase activity. The protein was reacted with varying concentrations of the substrate and the
enzyme activity was plotted against substrate concentration in both cases using the Line- Weaver
Burke plot (see appendix).
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The affinity of the protein for ASN was determined to be high with reactions occurring in
concentrations of ASN as low as 13.6µM and higher concentrations of GLN required for a
reaction with a Km of 850µM. Blood ASN concentration in humans are typically between 50 to
100µM while blood GLN concentrations are typically between 500 to 800µM[59], with the Km
displayed by the ASNase isolated from R. rhodochrous DAP 96253, efficient substrate binding
can be expected in the relatively low substrate concentrations present in human blood. Several
studies point to the fact that GLNase activity is not required for the antitumor activity of ASNase
and some studies have linked the side effects associated with the use of ASNase therapy directly
to the inherent GLNase activity[49,19]. There are other studies that point to GLNase activity
expressed by ASNase as being responsible for the effective treatment of ALL especially with
respect to ALL cell lines expressing the ASNS gene and are therefore capable of synthesizing
ASN using serum GLN[18,85,24]. With these opposing points of view about the ASNase/
GLNase activity and anticancer capabilities, it was determined that an ideal protein preparation
was one that exhibited a much stronger affinity for ASN over GLN.
With the relatively low substrate affinity displayed by the purified protein for GLN, it is
expected that if the protein is utilized as for ALL treatment, it will deplete serum ASN and
reduce the concentration of serum GLN to a point where the leukemic cells are negatively
impacted without necessarily bringing on the negative side effects tied to inherent GLNase
activity.
4.12 Effect of selected chemicals on ASNase activity of protein preparations purified from
induced cells of R. rhodochrous DAP 96253
A selected number of chemicals in varying concentrations were analyzed for their impact
on the ASNase and GLNase activity expressed by the purified protein obtained from induced
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cells of R. rhodochrous DAP 96253. Of all the evaluated chemicals, only FeSO4 was found to
positively influence the ASNase activity of the protein purification with almost 30% bump in
enzyme activity. The other chemicals were found to negatively impact the protein’s ASNase
activity with (NH4)2S2O8 having the least negative effect on ASNase activity and CuSO4 having
the most negative impact on ASNase activity (Fig 19). These findings are in line with a study
performed on ASNase obtained from B. lichenformis showed that treatment with ZnCl2, CaCl2
and βME negatively impacted the protein. S. brollosae NEAE-115 ASNase was found to be
unaffected by Na and Fe but improved by Mg and Co[29,67]
Interestingly, all the selected chemicals were found to completely inhibit the GLNase
activity of the purified protein. This phenomenon has been proposed as a means of obtaining
GLNase free protein preparation from induced cells of R. rhodochrous DAP 96253 which
exhibits ASNase activity.
4.13 The effect of protein preparations exhibiting ASNase and GLNase activity on
leukemia expressing cell lines
The two leukemia expressing cells that were selected to be utilized for this study were
Jurkat clone E6-1 (ATCC® TIB-152TM) and Molt-4 (ATCC® CRL-1582TM) cell lines. The
Jurkat cells were selected because they have been shown to express ASNS and are believed to be
resistant to GLNase free ASNase protein preparations[65], and the Molt-4 cells were selected
because they are ALL expressing cell line isolated from a patient who underwent chemotherapy
to treat ALL.
96 well plates were incubated with 1.2 x 104 cells/ well for the case of Jurkat cells and 3.0
x 105 cells/ well in the case of Molt-4 cells. The increase in the number of Molt-4 cells utilized
for the study was prompted by the results from an initial setup using 1.2 x 104 cells/ well. It was
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observed that after 24 hours of growth, all the cells present in the 2x through 4x dose treatments
were dead and after 48 hours, all the treated cells were dead (results not shown).
The results from the study indicate that the protein preparation exhibiting ASNase and
GLNase activity was cytotoxic against both cell lines tested, decreasing cell numbers and
viability with protein dose and time. Jurkat cells typically grow in clusters (Fig 20 and Fig 26),
with the increasing protein dose and treatment time, Jurkat cell clusters were found to reduce in
size. The IC50 for Jurkat E6-1 clone was determined to be 0.123 IU/mg and 1.982 IU/mg for
Molt-4 cells.
In conclusion, the purified protein preparation obtained from induced cells cells of R.
rhodochrous DAP 96253 has been demonstrated to be functional at physiological human pH and
temperature, endotoxin free, possessing a high affinity for ASN and antileukemic against Jurkat
clone E6-1 and Molt-4 cell lines. All of these results suggest that the protein preparation will
serve as a suitable alternative for the treatment of ALL.
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APPENDICES
Appendix A
Lysis buffers; Sodium phosphate (pH 5.8, 6.0, 7.2, 7.4, 7.6, 7.8) Tris-HCl (pH 8.0, 9.0),
typically incorporating 2-mercaptoethanol at 5mM concentration and glycerol at 5%
concentration
Dialysis buffers; Sodium phosphate (pH 7.0, 7.2 and 7.6) incorporating 2mercaptoethanol at 5mM concentration, glycerol at 5% concentration and Magnesium sulfate
heptahydrate (J.T. Baker) at 1% concentration.
Purification buffers; Sodium phosphate buffer (pH 6.0, 7.0, 7.2, 7.4, 7.6, 8.0), potassium
phosphate buffer (pH 7.6), MOPS buffer (pH 7.2), Tris-HCl buffer (pH 8.0, 9.0). AEX elution
buffers incorporate 1M NaCl
pH Study buffers: Citrate buffer (pH 3.0, 4.0, 5.0), Sodium phosphate buffer (pH 6.0, 7.0,
7.2, 7.4, 7.6, 7.8, 8.0), Tris HCl buffer (pH 8.0, 9.0, 10.0), Glycine-NaOH buffer (pH 9.0, 10.0).
Appendix B
▪

Total enzyme activity =µmols of the product/ (reaction time x enzyme volume)

▪

Specific activity determined by dividing the international units of the enzyme by the total
protein concentration expressed in IU/mg.

▪

Fold purification of the protein is determined by dividing the specific activity of the
purified fraction by the specific activity of the CFL.

▪

Percentage yield is determined by dividing the total activity of the purified fraction by the
total activity of the CFL.
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Appendix C
Lineweaver-Burk plot equation
1/V=Km/Vmax х 1/[S] + 1/Vmax
Based on the linear plot
y= mx + b
y= 1/V
m= Km/Vmax
x= 1/ [S]
b= 1/Vmax
Vmax= 1/b
Km= (Vmax) x (m)

